Strategic Growth Pegasus Laboratories is expanding its footprint with a Pensacola facility expansion in 2025 and plans for additional manufacturing capacity, presenting opportunities to introduce additive contracts, fill-finish partnerships, and scalable production services for veterinary pharmaceuticals and nutraceuticals.

Talent Expansion The company added nearly 70 new positions during its expansion and appointed a new VP of Sales and Commercial Operations in 2026, signaling a proactive push to grow revenue streams, improve customer acquisition, and deepen market coverage in animal health and related segments.

Broad Service Roadmap As a full-service CDMO with cGMP and DEA approval offering development to commercialization, Pegasus presents cross-sell opportunities across formulation development, process optimization, tech transfer, and regulatory support for both animal health products and PRN Pharmacal labeled items.

Acquisition & Trials Recent acquisition of TriviumVet and ongoing Liavium-CA1 pivotal trial indicate a strategy of expanding product candidates and clinical programs, providing possible collaboration on co-development, licensing, or contract manufacturing for trial materials and early-scale production.

Strategic Partnerships As a 100% employee-owned, customer-focused CDMO with ties to PBI-Gordon and a growing customer base, Pegasus can be positioned as a reliable, quality-driven partner for veterinary manufacturers seeking turnkey solutions, accelerated time-to-market, and robust quality systems.